title: Complete remission of previously intractable peripheral cutaneous T-cell lymphoma of the lower extremity using isolated hyperthermic limb perfusion with melphalan (1-phenylalanine mustard).
abstract: The patient is a 74-year-old woman first diagnosed with a peripheral cutaneous T-cell lymphoma (PCTCL) in April of 1994. Initially she presented with subcutaneous indurated areas in the right forearm, scapula, and submadibular region. After chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), she went into remission for 2 years before relapse of her PCTCL localized to the right lower extremity. Persistent isolated disease in the extremity since then led to numerous chemotherapy regimens and localized radiation therapy. Due to dramatic limb threatening progression of the disease in 2001, she underwent isolated hyperthermic limb perfusion with melphalan (1-phenylalanine mustard). Although limb preservation could not be achieved, this treatment resulted in complete clinical and pathological regression of the lesions of the perfused extremity.
authors.affiliation: Department of Surgery, Mount Sinai Medical Center, Miami Beach, Florida 33140, USA. jcparamo@med411.com
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Paramo
authors.forename: Carlos
authors.initials: C
authors.lastname: Benavides
authors.forename: Lawton W
authors.initials: LW
authors.lastname: Tang
authors.forename: Antonio
authors.initials: A
authors.lastname: Martinez
authors.forename: Beria
authors.initials: B
authors.lastname: Cabello-Inchausti
authors.forename: Enrique
authors.initials: E
authors.lastname: Davila
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Mesko
mesh_terms: D000368:Aged; D000671:Amputation, Surgical; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D035002:Lower Extremity; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan